Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q4 2022 · 10-K
Revenue$128.43M$128.43M−3.6% vs Q4 2021 Net Income-$37.30M-$37.30MN/M vs Q4 2021 EPS Diluted-$0.36-$0.36N/M vs Q4 2021 Gross Profit$99,541,000−3.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,707,000N/M Free Cash Flowderived-$10,138,000N/M Margins · derivedGross margin77.5%−0.2 pt vs Q4 2021
Operating margin-33.5%−15.9 pt vs Q4 2021
Net margin-29.0%−9.2 pt vs Q4 2021
ended Dec 31, 2022 · filed Feb 23, 2023 · 54 d after period end